Scholarlink

<p>Interleukin-6 (IL-6) is a multifunctional cytokine with important functions in health and disease. In order to activate its target cells, IL-6 binds first to the IL-6 receptor (IL-6R), which in turn induces the recruitment and homodimerization of the signal-transducing β-receptor gp130 and the activation of intracellular signaling cascades, including the phosphoinositide 3-kinase (PI3K)-AKT cascade. IL-6 is involved in the pathogenesis of multiple inflammatory diseases, and tocilizumab, a monoclonal antibody that binds to the IL-6R and thus blocks the biological activities of IL-6, is in clinical use worldwide for the treatment of patients with inflammatory diseases, including rheumatoid arthritis. Recently, Weng and colleagues published a paper in <i>Naunyn–Schmiedeberg’s Archives of Pharmacology</i> describing paradoxical effects of tocilizumab when used on murine cells in vitro and in a rat model of acute lung injury in vivo. In this communication, I provide evidence that the results presented by Weng and colleagues are not compatible with what is known about the biology of IL-6 and highlight why the provided evidence is insufficient to believe that tocilizumab shows the reported paradoxical effects in rodents.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

No evidence for paradoxical effects of tocilizumab in rodents

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月12日

查看全文
  • Christoph Garbers

摘要

Interleukin-6 (IL-6) is a multifunctional cytokine with important functions in health and disease. In order to activate its target cells, IL-6 binds first to the IL-6 receptor (IL-6R), which in turn induces the recruitment and homodimerization of the signal-transducing β-receptor gp130 and the activation of intracellular signaling cascades, including the phosphoinositide 3-kinase (PI3K)-AKT cascade. IL-6 is involved in the pathogenesis of multiple inflammatory diseases, and tocilizumab, a monoclonal antibody that binds to the IL-6R and thus blocks the biological activities of IL-6, is in clinical use worldwide for the treatment of patients with inflammatory diseases, including rheumatoid arthritis. Recently, Weng and colleagues published a paper in Naunyn–Schmiedeberg’s Archives of Pharmacology describing paradoxical effects of tocilizumab when used on murine cells in vitro and in a rat model of acute lung injury in vivo. In this communication, I provide evidence that the results presented by Weng and colleagues are not compatible with what is known about the biology of IL-6 and highlight why the provided evidence is insufficient to believe that tocilizumab shows the reported paradoxical effects in rodents.